Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Mischo

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Therapeutische Umschau. Revue Therapeutique|September 28, 2017
Niels J Rupp, Axel Mischo, Holger Moch
Immunological Investigations|December 29, 2007
Characterizing host immune responses by monitoring fluorescently marked cellsAxel Mischo, Cheryl Eppolito, Qingsheng Li, et al.
Current Drug Targets|January 27, 2015
Oncotargets in different renal cancer subtypesHolger Moch, Rodolfo Montironi, Antonio Lopez-Beltran, et al.
BMC Cancer|August 18, 2016
Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevanceCaroline Razafinjatovo, Svenja Bihr, Axel Mischo, et al.
Immunologic Research|October 28, 2009
Regulating functional cell fates in CD8 T cellsProtul A Shrikant, Rajesh Rao, Qingsheng Li, et al.
International Journal of Cancer|September 24, 2004
Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2Frank Neumann, Claudia Wagner, Stefan Stevanovic, et al.
Cancer Immunity|December 18, 2003
Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2Claudia Wagner, Frank Neumann, Boris Kubuschok, et al.
Anticancer Research|October 15, 2013
Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free systemGopinadh Jakka, Petra C Schuberth, Markus Thiel, et al.
International Journal of Oncology|May 17, 2011
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysisAxel Mischo, Nina Bubel, Jonathan S Cebon, et al.
International Journal of Cancer|June 30, 2005
Characterization of Hap/BAG-1 variants as RP1 binding proteins with antiapoptotic activityAndreas Wadle, Axel Mischo, Philipp P Henrich, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Therapeutische Umschau. Revue Therapeutique|September 28, 2017
Niels J Rupp, Axel Mischo, Holger Moch
Immunological Investigations|December 29, 2007
Characterizing host immune responses by monitoring fluorescently marked cellsAxel Mischo, Cheryl Eppolito, Qingsheng Li, et al.
Current Drug Targets|January 27, 2015
Oncotargets in different renal cancer subtypesHolger Moch, Rodolfo Montironi, Antonio Lopez-Beltran, et al.
BMC Cancer|August 18, 2016
Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevanceCaroline Razafinjatovo, Svenja Bihr, Axel Mischo, et al.
Immunologic Research|October 28, 2009
Regulating functional cell fates in CD8 T cellsProtul A Shrikant, Rajesh Rao, Qingsheng Li, et al.
International Journal of Cancer|September 24, 2004
Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2Frank Neumann, Claudia Wagner, Stefan Stevanovic, et al.
Cancer Immunity|December 18, 2003
Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2Claudia Wagner, Frank Neumann, Boris Kubuschok, et al.
Anticancer Research|October 15, 2013
Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free systemGopinadh Jakka, Petra C Schuberth, Markus Thiel, et al.
International Journal of Oncology|May 17, 2011
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysisAxel Mischo, Nina Bubel, Jonathan S Cebon, et al.
International Journal of Cancer|June 30, 2005
Characterization of Hap/BAG-1 variants as RP1 binding proteins with antiapoptotic activityAndreas Wadle, Axel Mischo, Philipp P Henrich, et al.
Pageof 3